Acute lymphocytic/lymphoblastic leukemia (ALL) is the most common type of cancer in children. Acute lymphocytic/lymphoblastic leukemia therapeutics are utilized for treating several acute leukemia such as Philadelphia chromosome, precursor B-cell ALL, and T-cell ALL. Chemotherapy, targeted therapy, radiation Therapy, and stem cell transplantation are the common ALL therapies, among which targeted therapy is the most preferred treatment method due to faster results.
Targeted Therapy: The Most Widely Used ALL Treatment Therapy
In 2016, chemotherapy was the largest segment due to easy availability and varied product portfolio. The therapy can be used as a single or in combination of drugs to treat ALL. It has the ability to terminate leukemia cells and prevent thriving and multiplication of the cells; which is also said to help boost the segment demand. It includes alkylating agents, antimetabolites, cytotoxic agents, and other plant derivatives. Demand for chemotherapy regimen such as oncaspar and CALGB 8811 is extremely high.
For instance, Shire plc. developed a new formulation for ONCASPAR (pegaspargase), which received an approval from the European Commission in December 2017. This approval allows product to be used as a constituent of antineoplastic combination therapy for treating ALL in pediatric patients from birth to 18 years of age and in adult patients.
On the other hand, targeted therapy segment is expected to be the fastest-growing segment over the forecast period (2017 to 2025). The therapy offers advantages such as greater accuracy and efficiency of treatment with earlier recovery as compared to chemotherapy, which is likely to increase the preference for targeted therapies.
Market Overview
According to a report by Grand View Research, Inc., the worldwide acute lymphocytic/lymphoblastic leukemia therapeutics market is likely to attain USD 3.4 billion by 2025. Factors such as increasing incidences of lymphocytic leukemia (ALL) and positive initiatives by government and private firms for development of innovative therapies can propel the ALL therapeutics market over the forecast period. Asia Pacific is likely to show rapid growth and expected to expand at a lucrative CAGR owing to rising awareness about ALL. Leading companies in the market include Spectrum Pharmaceuticals, Inc.; Genzyme Corporation; Erytech Pharma; Sigma-Tau s.p.a., and Pfizer, Inc.
Click here:
Click here:
No comments:
Post a Comment